US Patent Issued to Genzyme on March 24 for "6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity" (New Jersey Inventors)

ALEXANDRIA, Va., March 24 -- United States Patent no. 12,583,824, issued on March 24, was assigned to Genzyme Corp. (Cambridge, Mass.).

"6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient CFTR activity" was invented by Zhongli Gao (Bridgewater, N.J.), Gregory Hurlbut (Bridgewater, N.J.), Mark Munson (Bridgewater, N.J.) and Junkai Liao (Bridgewater, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention relates to heteroaryl compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficien...